{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T21:00:39Z","timestamp":1754600439270,"version":"3.41.2"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.<\/jats:p>","DOI":"10.1097\/mca.0000000000000976","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T01:15:36Z","timestamp":1606180536000},"page":"340-344","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia"],"prefix":"10.1097","volume":"32","author":[{"given":"Chiara","family":"Schimmenti","sequence":"first","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Science and Technologies"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Sucato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Manzone","sequence":"additional","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Science and Technologies"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cancellieri","sequence":"additional","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Science and Technologies"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Mortillaro","sequence":"additional","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Science and Technologies"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo Ruggero","family":"Galassi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Venturella","sequence":"additional","affiliation":[{"name":"Department of Biological, Chemical and Pharmaceutical Science and Technologies"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4081\/jbr.2013.3677","article-title":"Metabolic syndrome and cognitive decline: the role of physical activity.","volume":"86","author":"Rinaldi","year":"2013","journal-title":"J Biol Res"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2174\/0929867326666190516103953","article-title":"Lipoproteins in atherosclerosis process.","volume":"26","author":"Arnao","year":"2019","journal-title":"Curr Med Chem"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/1568026053544524","article-title":"New lipid-lowering agents acting on LDL receptors.","volume":"5","author":"Scharnagl","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"101006","DOI":"10.1016\/j.plipres.2019.101006","article-title":"ATP-citratelyase(ACLY)in lipid metabolism and atherosclerosis: an updated review.","volume":"77","author":"Fenga","year":"2020","journal-title":"Progression Lipid Res"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","article-title":"ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.","volume":"20","author":"Ruscica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase.","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000565","article-title":"Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.","volume":"30","author":"Burke","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13543784.2017.1280458","article-title":"Evaluating bempedoic acid for the treatment of hyperlipidaemia.","volume":"26","author":"Penson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CRD.0000000000000218","article-title":"Bempedoic Acid (ETC-1002): ATP citrate lyase inhibitor: review of a first-in-class medication with potential benefit in statin-refractory cases.","volume":"27","author":"Zagelbaum","year":"2019","journal-title":"Cardiol Rev"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/s12349-012-0097-8","article-title":"Dietary strategy for prevention and management of dyslipidemia: international guidelines.","volume":"5","author":"Sucato","year":"2012","journal-title":"Mediterranean J Nutrition Metabolism"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MOL.0000000000000390","article-title":"ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.","volume":"28","author":"Burke","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"R13-20250729","first-page":"257","article-title":"Bempedoic Acid (ETC-1002): a current review.","volume":"36","author":"Saeed","year":"2018","journal-title":"Cardiol Clin"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR+\/- and LDLR-\/-) yucatan miniature pigs.","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jama.2019.16598","article-title":"Bempedoic acid for lowering LDL cholesterol.","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial.","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"R17-20250729","first-page":"2047487319864672","article-title":"Bempedoic acid and ezetimibe - better together.","volume":"16","author":"Khan","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"R19-20250729","doi-asserted-by":"crossref","DOI":"10.1007\/s40256-020-00399-w","article-title":"A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia.","author":"Niman","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"e012352","DOI":"10.1161\/JAHA.119.012352","article-title":"CLEAR serenity trial: more clarity for the future of bempedoic acid in patients unable to take statins?","volume":"8","author":"Jia","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"R23-20250729","first-page":"2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"29","author":"Ballantyne","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2019","journal-title":"Eur J Prev Cardiol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:08:01Z","timestamp":1753812481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000976","relation":{},"ISSN":["0954-6928"],"issn-type":[{"type":"print","value":"0954-6928"}],"subject":[],"published":{"date-parts":[[2020,11,20]]}}}